Drug Trial Radar · NCT04753697
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Last checked: Nov 19, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
430
Actual
Start
Feb 22, 2021
Primary completion
Jan 11, 2024
Study completion Aug 29, 2024
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Feb 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase. Participants will be randomized at the beginning of the study into 3 treatment arms: * Placebo for Induction and Maintenance * CC-93538 360 mg Subcutaneous (SC) once weekly for Induction followed by 360 mg SC once every other week for Maintenance * CC-93538 360 mg SC once weekly for Induction and Maintenance
Conditions
- Eosinophilic Esophagitis
Interventions
CC-93538Drug
Subcutaneous
PlaceboOther
Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Dysphagia Days (DD) at Week 24Time frame: Baseline (Day 1) and Week 24
- Percentage of Participants With Peak Esophageal Eosinophil Count <= 6/High-power Field (Hpf) at Week 24Time frame: Week 24
Locations
212 sites in 15 countries. Site status is shown where the registry gives one.
Local Institution - 144
Birmingham, Alabama
Local Institution - 158
Tuscaloosa, Alabama
Local Institution - 082
Phoenix, Arizona
Local Institution - 147
Phoenix, Arizona
Local Institution - 041
Scottsdale, Arizona
Local Institution - 029
Tucson, Arizona
Local Institution - 165
North Little Rock, Arkansas
Local Institution - 075
Lancaster, California
Local Institution - 047
Los Angeles, California
Local Institution - 084
Oakland, California
Local Institution - 160
San Diego, California
Local Institution - 068
Aurora, Colorado
Local Institution - 067
Colorado Springs, Colorado
Local Institution - 092
Denver, Colorado
Local Institution - 170
Littleton, Colorado
Local Institution - 128
Wheat Ridge, Colorado
Local Institution - 101
Bristol, Connecticut
Local Institution - 076
Farmington, Connecticut
Local Institution - 156
Hamden, Connecticut
Local Institution - 099
Clearwater, Florida
Local Institution - 036
Inverness, Florida
Local Institution - 042
Jacksonville, Florida
Local Institution - 161
Miami, Florida
Local Institution - 138
Miami, Florida
Local Institution - 110
North Miami Beach, Florida
Local Institution - 146
Orlando, Florida
Local Institution - 088
Orlando, Florida
Local Institution - 133
Orlando, Florida
Local Institution - 169
Pinellas Park, Florida
Local Institution - 168
Plantation, Florida
Local Institution - 037
Port Orange, Florida
Local Institution - 140
Sweetwater, Florida
Local Institution - 043
Atlanta, Georgia
Local Institution - 171
Atlanta, Georgia
Local Institution - 054
Atlanta, Georgia
Local Institution - 117
Macon, Georgia
Local Institution - 024
Idaho Falls, Idaho
Local Institution - 039
Chicago, Illinois
Local Institution - 167
Gurnee, Illinois
Local Institution - 118
Indianapolis, Indiana
Showing 40 of 212 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.